Aldeyra Therapeutics
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Aldeyra Therapeutics generated cash of -$30,326,128, which is more than the previous year. Cash used in financing activities reached the amount of -$1,270,220 last year. Net change in cash is therefore -$1,596,348.
Cash Flow
| 2014 | -4.77M | -14.06K | 10.05M |
|---|---|---|---|
| 2015 | -9.31M | -13.03M | 28.46M |
| 2016 | -15.14M | -225.23K | 12.73M |
| 2017 | -19.22M | -10.19M | 37.42M |
| 2018 | -29.85M | -23.33M | 80.52M |
| 2019 | -44.98M | 18.47M | 23.57M |
| 2020 | -37.49M | 29.02M | 41.90M |
| 2021 | -42.55M | -7.80K | 194.49M |
| 2022 | -56.63M | -29.95M | 1.22M |
| 2023 | -30.32M | 30M | -1.27M |
ALDX Cash Flow Statement (2014 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 144.41M | 229.79M | 77.85M | 44.42M | 47.35M | 20.02M | 12.01M | 14.64M | 8.52M | 3.26M |
Operating activities | ||||||||||
Net income | -37.54M | -62.02M | -57.77M | -37.55M | -60.82M | -38.89M | -22.34M | -18.69M | -12.09M | -5.18M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||||
Depreciation and amortization | 262.78K | 258.70K | 264.18K | 56.22K | 96.30K | 71.00K | 37.84K | 35.79K | 18.77K | 1.06K |
Stock-based compensation expense | 5.75M | 8.28M | 7.10M | 7.08M | 8.08M | 0 | 2.71M | 2.75M | 2.18M | 2.03M |
| Deferred income tax benefit | 5.75M | 8.28M | 7.10M | 7.08M | 8.08M | 0 | 2.71M | 2.75M | 2.18M | 2.03M |
| Changes in operating assets and liabilities: | ||||||||||
Accounts receivable, net | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accounts payable | 1.20M | -886.07K | 638.06K | -426.66K | -2.84M | 2.04M | 725.52K | -575.71K | 509.86K | -559 |
Cash generated by operating activities | -30.32M | -56.63M | -42.55M | -37.49M | -44.98M | -29.85M | -19.22M | -15.14M | -9.31M | -4.77M |
Investing activities | ||||||||||
Purchases Of Investments | 0 | -92.93M | 0 | -5.77M | -57.76M | -59.73M | -35.09M | -16.04M | -12.95M | 0 |
Investments In Property Plant And Equipment | 0 | -16.31K | -7.80K | 0 | -9.52K | -262.96K | -24.75K | -11.81K | -86.11K | -14.06K |
Acquisitions Net | 0 | 16.31K | 0 | 0 | 609.46K | 262.96B | 24.75B | 11.81K | 0 | 0 |
Cash generated by investing activities | 30M | -29.95M | -7.80K | 29.02M | 18.47M | -23.33M | -10.19M | -225.23K | -13.03M | -14.06K |
Financing activities | ||||||||||
Common Stock Issued | 305.23K | 1.12M | 189.81M | 41.90M | 7.89M | 81.92M | 37.59M | 12.73M | 28.50M | 10.05M |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | -532.95K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repayments of term debt | -1.04M | 0 | 0 | 0 | 14.45M | 0 | 0 | 0 | 0 | -1.39M |
Cash used in financing activities | -1.27M | 1.22M | 194.49M | 41.90M | 23.57M | 80.52M | 37.42M | 12.73M | 28.46M | 10.05M |
Net Change In Cash | -1.59M | -85.37M | 151.93M | 33.43M | -2.93M | 27.33M | 8.00M | -2.63M | 6.12M | 5.26M |
Cash at end of period | 142.82M | 144.41M | 229.79M | 77.85M | 44.42M | 47.35M | 20.02M | 12.01M | 14.64M | 8.52M |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source |